All In Biotech

Drug Trial Radar · NCT00525798

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

Last checked: Nov 19, 2026Latest source record: Oct 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,665 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,665

Actual

Start

Mar 2007

Primary completion

Aug 2011

Study completion Nov 2011

Sponsor

Lead sponsor
Nordic Bioscience A/SIndustry
Sponsor type
Industry
Collaborators
Novartis
First posted
Sep 6, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoporosis

Conditions

  • Osteoporosis

Interventions

  • SMC021 Oral calcitoninDrug

    0.8mg SMC021 - oral calcitonin, once daily

  • SMC021 PlaceboDrug

    SMC021 - Placebo, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With New Vertebral FracturesTime frame: From baseline to month 36

Locations

16 sites in 12 countries. Site status is shown where the registry gives one.

  • United Osteporosis Centers

    Gainesville, Georgia

  • Michigan Bone & Mineral Clinic PC,

    Detroit, Michigan

  • Oregon Osteoporosis Center

    Portland, Oregon

  • CCBR Brazil

    Rio de Janeiro, Brazil

  • CCBR China

    Beijing, China

  • CCBR Czech

    Pardubice, Czechia

  • CCBR Aalborg

    Aalborg, Denmark

  • CCBR Ballerup

    Ballerup Municipality, Denmark

  • CCBR Vejle

    Vejle, Denmark

  • CCBR Estonia

    Tallinn, Estonia

  • Hopital Edouard Herriot

    Lyon, France

  • CCBR Hong Kong

    Hong Kong, Hong Kong

  • Department of Internal Medicine, University of Florence

    Florence, Italy

  • CCBR Lithuania

    Vilnius, Lithuania

  • CCBR Poland

    Warsaw, Poland

  • CCBR Romania

    Bucharest, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.